Inogen, Inc. INGN announced preliminary revenues for the fourth quarter and full year 2024 on Monday. Following the robust ...

Stifel Nicolaus analyst Mathew Blackman maintained a Hold rating on Inogen (INGN – Research Report) yesterday and set a price target of ...

Recent Development for INGN In October, INGN announced that it had commenced the U.S. market release of the Inogen Rove 4 Portable Oxygen Concentrator. The Rove 4 utilizes Inogen’s patented ...

GOLETA, Calif., January 13, 2025--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today ...

Needham analyst Michael Matson has maintained their neutral stance on INGN stock, giving a Hold rating yesterday.Stay Ahead of the ...

Inogen, Inc. INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid second-quarter 2024 ...

Jane Street Group LLC trimmed its holdings in Inogen, Inc. (NASDAQ:INGN – Free Report) by 83.1% during the third quarter, ...

Inogen, Inc. (NASDAQ: INGN) is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid first-quarter ...

INGN announces FDA clearance for the SIMEOX 200 Airway Clearance Device. The latest announcement is out from Inogen ( (INGN) ). Inogen, Inc. announced that it has received FDA 510(k) clearance for ...

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced unaudited preliminary revenue results for the ...

Inogen, Inc. INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid second-quarter 2024 ...